DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20184922

C-reactive protein as a screening test for gestational diabetes mellitus in first-trimester of pregnancy: a prospective cohort study

Tarek A. Farghaly, Neveen A. Helmy, Ahmed M. Abbas, Abdel Ghaffar M. Ahmed

Abstract


Background: The current study aims to determine if increased inflammation identified by increased C-reactive protein (CRP) level is associated with the subsequent development of gestational diabetes mellitus (GDM).

Methods: A prospective cohort study conducted at a tertiary University Hospital included 496 booking for their antenatal care visit between 10-12 weeks of gestation. They were tested for presence of CRP in blood. All women without a history of antenatal type 1 or type 2 diabetes undergo routine GDM screening with the 50-g oral glucose-loading test (GLT) between 24 and 28 weeks 'gestation. Women whose 1-h post-loading plasma glucose level >7.8 mmol/l (>140 mg/dl) undergo a diagnostic, fasting, 100-g, 3-h oral glucose tolerance test (OGTT) within 1-2 weeks following the GLT.

Results: Among these 496 women, a total of 27 women (5.4%) were diagnosed as GDM and 10 women (2.0%) were diagnosed as IGT at week 24-28. The CRP was positive and higher in the GDM diagnosed group (p=0.000) compared to those who did not develop GDM. CRP was positively correlated with diagnosis of GDM (r=0.438, p=0.012).

Conclusions: There is an association between first-trimester inflammation, marked by increased CRP levels and subsequent risk of GDM.


Keywords


C-reactive protein, Gestational diabetes mellitus, Glucose tolerance test

Full Text:

PDF

References


National Institutes of Health consensus development conference statement: diagnosing gestational diabetes mellitus, March 4-6. Obstet Gynecol. 2013;122(Pt 1):358-69.

Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361:1339-48.

Beischer NA, Wein P, Sheedy MT, Steffen B. Identification and treatment of women with hyperglycaemia diagnosed during pregnancy can significantly reduce perinatal mortality rates. Aust N Z J Obstet Gynaecol. 1996;36(3):239-47.

HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002.

Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012:DC111790.

Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Australian carbohydrate intolerance study in pregnant women trial G. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-86.

Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-48.

Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH. Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks. Prenat Diagn. 2011;31(2):135-41.

Maged AM, Moety GA, Mostafa WA, Hamed DA. Comparative study between different biomarkers for early prediction of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2014;27(11):1108-12.

Yeral MI, Ozgu-Erdinc AS, Uygur D, Seckin KD, Karsli MF, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester, comparison of fasting plasma glucose, two-step and one-step methods: a prospective randomized controlled trial. Endocrine. 2014;46(3):512-8.

Nahum GG, Wilson SB, Stanislaw H. Early-pregnancy glucose screening for gestational diabetes mellitus. J Reprod Med. 2002;47(8):656-62.

National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. London: Clinical Guidelines, 2015.

American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015;33:97-111.

Gupta Y, Kalra B, Baruah MP, Singla R, Kalra S. Updated guidelines on screening for gestational diabetes. Int J Womens Health. 2015;7:539-50.

International association of diabetes and pregnancy study groups consensus panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676-82.

Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. Obstet Gynecol. 2013;122(Pt 1):406-16.

Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab. 2009;94:2464-70.

Kim SY, England JL, Sharma JA, Njoroge T. Gestational diabetes mellitus and risk of childhood overweight and obesity in offspring: a systematic review. Exp Diabetes Res. 2011;54:130-8.

McMillen IC, Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev. 2005;85:571-633.

Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care. 2008;31:340-6.

Li X, X Lu. Study on correlation between C-reactive protein and gestational diabetes mellitus. J Nanjing Med Univ. 2007;21(6):382-5.

Liu T, Fang Z, Yang D, Liu Q. Correlation between the inflammatory factors and adipocytokines with gestational diabetes mellitus and their change in puerperium. Zhonghua Fu Chan Ke Za Zhi. 2012;47(6):436-9.

Rota S, Yildirim B, Kaleli B, Aybek H, Duma K, Kaptanoglu B. C-reactive protein levels in non-obese pregnant women with gestational diabetes. Tohoku J Exp Med. 2005;206:341-5.

Qiu C, Sorensen TK, Luthy DA, Williams MA. Prospective study of maternal serum C-reactive protein (CRP) concentrations and risk of gestational diabetes mellitus. Paediatr Perinat Epidemiol. 2004;18(5):377-84.

Wolf M, Sauk J, Shah A, Smirnakis KV, Jimenez-Kimble R, Ecker JL, et al. Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. Diabetes Care. 2004;27:21-7.

Radaelli T, Varastehpour A, Catalano P, Hauguel-de Mouzon S. Gestational diabetes induces placental genes for chronic stress and inflammatory pathways. Diabetes. 2003;52(12):2951-8.

Ahi Z, Kariman N, Asl SZ, Shakeri N. Diagnostic value of C–reactive protein in determining of gestational diabetes mellitus (GDM). Biosci Biotechnol Res Asia. 2016;13(2):743-50.

Mohan BS. C-reactive protein in early months of pregnancy as a screening test for gestational diabetes mellitus developing in later months of pregnancy. J Obstet Gynecol India. 2006;56:131-3.

Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L, Friedman JE, et al. TNF-α is a predictor of insulin resistance in human pregnancy. Diabetes. 2002;51(7):2207-13.

Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. C reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab. 2003;88(8):3507- 12

Frohlich M, Emhof A, Berg G, Hutchinson W, Pepys M, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care. 2000;23:1835-9.

Cunningham FG, et al. Williams Obstetrics. 24th ed. New York: Wendel T; 2014.

Syngelaki A, Visser GH, Krithinakis K, Wright A, Nicolaides KH. First trimester screening for gestational diabetes mellitus by maternal factors and markers of inflammation. Metabol. 2016;65(3):131-7.

Corcoran S, Achamallah N, John OL, Grainne K, Stafford P, Meaney S, et al. Can first trimester high-sensitivity C-reactive protein and sex hormone binding globulin predict the onset of gestational diabetes? a prospective study of a high risk cohort. Am J Obstet Gynecol. 2016;214(1):S388.